Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
Abingdon Life Sciences, Inc. is a Drug, Device, Diagnostic Development Management Organization (DDMO), focused on providing drug and device companies with superior services based on an integrated strategic development model.
Abingdon Life Sciences, Inc. Announces Opening of Office in Carlsbad, Ca.
CARLSBAD, Calif., July 21 /PRNewswire/ -- Abingdon Life Sciences
announces the formal opening of its offices in Carlsbad, California. The
offices, located at 5963 La Place Court, Suite 107, are in the Carlsbad
Airport Business Park adjacent to Palomar Airport. Abingdon Life Sciences,
Inc. is a first-in-class Drug, Device, Diagnostic Development Management
Organization (DDMO), focused on providing drug and device companies with
superior services based on an integrated strategic development model. An
integrated development model focuses on the Target Product Profile (TPP)
concept, and allows a platform to be assessed by key areas of opportunity
and risk from both scientific and business aspects.
Abingdon was founded on the principle that a proactive strategic
approach to development will yield better outcomes. Abingdon's philosophy
is to provide clients with a focused approach to product development by
building synergistic partnerships that use significant expertise to achieve
the best outcome. Global core-competencies include pre-clinical, regulatory
strategy and submissions, clinical development, biostatistics, report
writing and post-marketing obligations. Abingdon provides services to
clients with products initially filed under IND, CTX, 505(b)(2), NDA, ANDA,
PMA and 510k applications. Abingdon's senior executives provide
personalized oversight and leadership of projects to ensure the best
possible customer experience. Key alliances enable Abingdon to assist with
cGMP services from formulation development for clinical trial supply
through commercialization.
"Abingdon's approach is to reduce the noise in the development process
and provide objective direction that outlines the risks and benefits of the
potential development pathways. In the end, our goal is to assist our
clients to streamline their development process and help make decisions
that will achieve their goals. We believe this will ultimately reduce costs
to our clients and speed the time to market," stated Aidan Nuttall, Ph.D.,
President and C.O.O., Abingdon Life Sciences, Inc.
About Abingdon Life Sciences, Inc.:
Abingdon Life Sciences, Inc. is a first-in-class Drug and Device
Development Management Organization (DDMO) providing drug and device
companies superior clinical and regulatory services based on an integrated
strategic development model. Abingdon's senior executives provide
personalized oversight and leadership of projects to ensure the best
possible customer experience.
SOURCE Abingdon Life Sciences, Inc.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
